A nation-wide study will be conducted in Jordan by AstraZeneca and the Jordanian Endocrinology Society to gauge "under-treatment" of high blood cholesterol in the kingdom, Jordan Times has reported. The study is part of an international survey that is designed to determine levels of cholesterol control among patients currently undergoing treatment, according to Ayman Hammoudeh, a consultant interventional cardiologist. The latest studies conducted in the kingdom indicate that Jordan is among countries with a high incidence of high blood cholesterol.